FSME antibodies
(Spring-summer encephalitis, tick-borne encephalitis TBE, early summer meningoencephalitis ESME)
Material: | Antibody demonstration: 1 ml serum, 2 ml CSF |
Methods: | Ligandenassays → Enzyme Linked Immunosorbent Assay (ELISA) | Criteria for evaluation | Serum: IgG: < 100 U/ml – 150 U/ml IgM: < 10 U/ml – 15 U/ml CSF: Please refer to findings report |
Indication | Neurological symptoms after tick-bite, checking of immunity status (Booster vaccinations recommended every 4 – 5 years) | Mandatory reporting | ja The laboratory has to report serological demonstration (IgM increase, fourfold IgG-antibody increase) to the health department, stating the patient’s name. |
Please note | Vaccination recommendation for persons in endemic areas. After FSME- vaccination there is insufficient immunity in 10 % of the cases. Endemic regions: South Germany (Bavaria, Baden-Württemberg), Austria, Switzerland, Croatia, Albany, Russia, Latvia, Czech Republic, Slovenia. Ixodes ricinus is the carrier, please see RKI map “FSME: Risikogebiete in Deutschland”. Following a tick-bite initial onset of fever with flu-like symptoms. Then a fever-free interval for about a week. Following this, another bout of fever with neurological symptoms (meningitis, encephalitis). In approximately 10 % of cases, there is lasting neurological damage. In many cases however, the course of infection is subclinical. Differential diagnostically borreliosis, possibly Ehrlichiosis, rickettsiosis, ECHO-virus-infection has to be ruled out. |
Accredited | ja |
More Results for the letter F
- Factor II activity (FACT01)
- Prothrombin
- Factor II mutation (FACT02)
- Prothrombin mutation G20210A
- Factor IX activity (FACT11)
- Factor V activity (FACT03)
- Factor V mutation Leiden (FACT04)
- Mutation: G1691A
- Factor VII activity (FACT05)
- Factor VIII activity (FACT06)
- Factor VIII inhibitor (FACT10)
- Factor VIII ristocetin cofactor (von Willebrand factor activity) (FACT08)
- vWF:activity
- Factor VIII von Willebrand factor antigen (FACT07)
- vWF:Ag
- Factor VIII von Willebrand multimers (FACT09)
- Factor X activity (FACT12)
- Factor XI activity (FACT13)
- Factor XII activity (FACT14)
- Hageman-Factor
- Factor XIII activity (FACT15)
- Syn.: fibrin stabilising factor
- Factor–II–activity (FAK2)
- Prothrombin
- Factor-II-mutation (FAK2GM)
- Prothrombin mutation G20210A
- Factor-IX-activity (FAK9)
- Factor-V-activity (FAK5)
- Factor-V-mutation Leiden (FAK5GM)
- Mutation: G1691A
- Factor-VII-activity (FAK7)
- Factor-VIII-activity (FAK8)
- Factor-VIII-inhibitor (FAK8IN)
- Bethesda assay
- Factor-X-activity (FAK10)
- Factor-XI-activity (FAK11)
- Factor-XII-activity (FAK12)
- Hageman factor
- Factor-XIII-activity (FAK13)
- Fibrin-stabilizing factor
- Fasciola hepatica (FASCI, FASCG)
- Common liver fluke
- Fat, total in stool (FETT1)
- Fatty acids, long-chained (LAFS)
- LCFA